PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 15, 20240 citationsOpen Access

Supplementary Figure S2 from First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors

View Full Paper
TYTimothy A. YapATAnthony W. TolcherRPRuth Plummer

Key Points

Key points are not available for this paper at this time.

Abstract

Figure S2. Change from baseline in tumor size and tuvusertib dose levels (FAS/SAF Analysis Set)

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Yap et al. (2024) studied this question.

synapsesocial.com/papers/68e6a14db6db643587624fbchttps://doi.org/10.1158/1078-0432.25826657
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Supplementary Figure S2 from First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors2024
  2. 2Supplementary Figure S4 from First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors2024
  3. 3Supplementary Figure S4 from First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors2024
  4. 4Supplementary Figure S1 from First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors2024
  5. 5Supplementary Figure S1 from First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors2024